- Home
- IMRN vs NERV Comparison
IMRN vs NERV Comparison
Compare IMRN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- NERV
- Stock Information
- Founded
- IMRN 1994
- NERV 2007
- Country
- IMRN Australia
- NERV United States
- Employees
- IMRN N/A
- NERV N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- NERV Health Care
- Exchange
- IMRN Nasdaq
- NERV Nasdaq
- Market Cap
- IMRN 15.0M
- NERV 15.5M
- IPO Year
- IMRN N/A
- NERV 2014
- Fundamental
- Price
- IMRN $1.90
- NERV $1.82
- Analyst Decision
- IMRN Strong Buy
- NERV Hold
- Analyst Count
- IMRN 1
- NERV 1
- Target Price
- IMRN $5.00
- NERV $5.00
- AVG Volume (30 Days)
- IMRN 4.7K
- NERV 77.1K
- Earning Date
- IMRN 03-03-2025
- NERV 03-04-2025
- Dividend Yield
- IMRN N/A
- NERV N/A
- EPS Growth
- IMRN N/A
- NERV N/A
- EPS
- IMRN N/A
- NERV N/A
- Revenue
- IMRN $3,271,194.00
- NERV N/A
- Revenue This Year
- IMRN N/A
- NERV N/A
- Revenue Next Year
- IMRN N/A
- NERV N/A
- P/E Ratio
- IMRN N/A
- NERV N/A
- Revenue Growth
- IMRN 171.67
- NERV N/A
- 52 Week Low
- IMRN $1.65
- NERV $1.77
- 52 Week High
- IMRN $5.96
- NERV $7.53
- Technical
- Relative Strength Index (RSI)
- IMRN 43.76
- NERV 34.70
- Support Level
- IMRN $1.89
- NERV $1.77
- Resistance Level
- IMRN $2.05
- NERV $2.05
- Average True Range (ATR)
- IMRN 0.08
- NERV 0.16
- MACD
- IMRN -0.02
- NERV -0.04
- Stochastic Oscillator
- IMRN 3.85
- NERV 6.41
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.